{
  "id": 5916,
  "text": "J Clin Oncol, 2015, 33 ( 19): 2129 - 2135.DOI: 10.1200 / JCO.2014.58.4391.[74] Coleman RL, Lorusso D, Gennigens C, et al.Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer ( innovaTV 204 / GOG-3023 / ENGOT-cx6) : a multicentre, open-label, single-arm, phase 2 study [ J ] .Lancet Oncol, 2021, 22 ( 5): 609 - 619.DOI: 10.1016 / S1470-2045 (21)00056-5.(编辑: 王雪萍)",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: J Clin Oncol, 2015, 33 ( 19): 2129 - 2135.DOI: 10.1200 / JCO.2014.58.4391.[74] Coleman RL, Lorusso D, Gennigens C, et al.Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer ( innovaTV 204 / GOG-3023 / ENGOT-cx6) : a multicentre, open-label, single-arm, phase 2 study [ J ] .Lancet Oncol, 2021, 22 ( 5): 609 - 619.DOI: 10.1016 / S1470-2045 (21)00056-\n\n<question>: \n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n",
  "ChatGPT_response_0": "根据现有研究数据，tisotumab vedotin在治疗先前接受过治疗的复发性或转移性宫颈癌患者中表现出一定的疗效和安全性证据。基于一项名为innovaTV 204/GOG-3023/ENGOT-cx6的多中心、开放标签、单臂、II期临床研究结果显示：\n\n1. **疗效**：研究表明，tisotumab vedotin能够对这类患者产生有效的治疗反应。具体而言，其客观缓解率（ORR）达到了显著水平，部分患者显示肿瘤体积缩小，临床获益明显。这为难治性宫颈癌的治疗提供了一种新的可能性。\n\n2. **安全性**：关于tisotumab vedotin的耐受性，研究中记录了相关的不良事件。主要的不良反应包括眼部毒性（如角膜炎或视力模糊）以及化疗相关的症状（如疲劳、恶心等）。尽管存在一定风险，这种治疗方案总体上被认为是可接受的。\n\n综上，tisotumab vedotin在复发或转移性宫颈癌的治疗中展现了具有临床意义的疗效，同时其安全性也在可控范围内，为既往治疗失败的患者提供了另一种治疗选择。",
  "query": "根据已提供的文本内容，以下是符合要求的<question>：\n\n**在治疗复发性或转移性宫颈癌时，已经接受过治疗的患者中，有哪些与tisotumab vedotin相关的疗效和安全性证据？**",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 根据已提供的文本内容，以下是符合要求的<question>：\n\n**在治疗复发性或转移性宫颈癌时，已经接受过治疗的患者中，有哪些与tisotumab vedotin相关的疗效和安全性证据？**\n\n<reference text>: J Clin Oncol, 2015, 33 ( 19): 2129 - 2135.DOI: 10.1200 / JCO.2014.58.4391.[74] Coleman RL, Lorusso D, Gennigens C, et al.Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer ( innovaTV 204 / GOG-3023 / ENGOT-cx6) : a multicentre, open-label, single-arm, phase 2 study [ J ] .Lancet Oncol, 2021, 22 ( 5): 609 - 619.DOI: 10.1016 / S1470-2045 (21)00056-5.(编辑: 王雪萍)\n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n\n<reply>: ",
  "response": "根据现有研究数据，tisotumab vedotin在治疗先前接受过治疗的复发性或转移性宫颈癌患者中表现出一定的疗效和安全性证据。基于一项名为innovaTV 204/GOG-3023/ENGOT-cx6的多中心、开放标签、单臂、II期临床研究结果显示：\n\n1. **疗效**：研究表明，tisotumab vedotin能够对这类患者产生有效的治疗反应。具体而言，其客观缓解率（ORR）达到了显著水平，部分患者显示肿瘤体积缩小，临床获益明显。这为难治性宫颈癌的治疗提供了一种新的可能性。\n\n2. **安全性**：关于tisotumab vedotin的耐受性，研究中记录了相关的不良事件。主要的不良反应包括眼部毒性（如角膜炎或视力模糊）以及化疗相关的症状（如疲劳、恶心等）。尽管存在一定风险，这种治疗方案总体上被认为是可接受的。\n\n综上，tisotumab vedotin在复发或转移性宫颈癌的治疗中展现了具有临床意义的疗效，同时其安全性也在可控范围内，为既往治疗失败的患者提供了另一种治疗选择。"
}